Markets
MNK

Weakness Seen in Relypsa (RLYP): Stock Falls 7.4% - Tale of the Tape

A generic image of a pen on a chart
Credit: Shutterstock photo

Relypsa, Inc. ( RLYP ) saw a big move in the last trading session, as the company's shares fell by over 7% on the day. The move came on pretty good volume too with far more shares changing hands than in a normal session. This continues the recent trend of the company, as the stock is now trading within the volatile price range of $21.39 to $25.41 in the past one-month time frame.

Although this slump was obviously disappointing, the company, a pharmaceutical firm specializing in non-absorbed polymeric drugs, has seen 1 positive revisions and its current year earnings consensus has moved higher over the past few weeks. This suggests that the recent slump might be a temporary blip on the radar for RLYP. So make sure to keep an eye on this stock going forward to see if yesterday's price decline is confirmed by more weakness, or if it can rebound in the weeks ahead.

RLYP currently holds a Zacks Rank #3 (Hold) while its Earnings ESP is positive.

Investors interested in the Medical- Generic Drugs industry may consider better-ranked stocks like Akorn, Inc. ( AKRX ), Mallinckrodt plc ( MNK ) and KaloBios Pharmaceuticals, Inc. ( KBIO ). While Akorn and Mallinckrodt hold a Zacks Rank #1 (Strong Buy), KaloBios carries a Zacks Rank #2 (Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

RELYPSA INC (RLYP): Free Stock Analysis Report

AKORN INC (AKRX): Free Stock Analysis Report

MALLINCKRODT PL (MNK): Free Stock Analysis Report

KALOBIOS PHARMA (KBIO): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

MNK

Other Topics

Investing Stocks

Latest Markets Videos

    Zacks

    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

    Learn More